CTOs on the Move

Allogene

www.allogene.com

 
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient`s own cells, simplifies manufacturing, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.allogene.com
  • 270 Littlefield Avenue
    South San Francisco, CA USA 94080
  • Phone: 650.457.2700

Executives

Name Title Contact Details
Nancy Saputra
 IT Director, Systems, Cloud, and Information Security Profile
Timothy Moore
 Chief Technical Officer Profile
Timothy Moore
 Chief Technology Officer Profile
Alison Moore
 Chief Technical Officer Profile
Alison Moore
 Executive Vice President of Operations and Chief Technical Officer Profile

Funding

Allogene raised $300M on 04/03/2018
Allogene raised $411.8M on 04/19/2018
Allogene raised $120M on 09/07/2018

Similar Companies

Celtaxsys

Celtaxsys is a privately-held clinical stage drug discovery and development company with operations in San Francisco, CA and Atlanta, GA.

Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children.

Coastal Pharma Group

Coastal Pharma Group is a Oxnard, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Risdall Marketing Group

Risdall Marketing Group is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Incyte

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than 1,000 employees are led by distinguished executives with proven records of success. We are proud to have been recognized by Forbes as one of the World`s Most Innovative Companies for each of the past three years.